Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2

Journal of Bone and Mineral Research

Volumn 19, Issue 4, 2004, Pages 652-660

  Kacena, Melissa A ^a   Shivdasani, Ramesh A ^b,c   Wilson, Kimberly ^a   Xi, Yougen ^a   Troiano, Nancy ^a   Nazarian, Ara ^d   Gundberg, Caren M ^a   Bouxsein, Mary L ^d   Lorenzo, Joseph A ^e   Horowitz, Mark C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Anabolic; Bone phenotype; Megakaryocytosis; Proliferation; Thrombocytopenia

Indexed keywords

ALKALINE PHOSPHATASE; OSTEOCALCIN; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR NF E2; DNA BINDING PROTEIN; ERYTHROID SPECIFIC DNA BINDING FACTOR; GATA1 PROTEIN, MOUSE; NFE2 PROTEIN, MOUSE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NF E2 P45 SUBUNIT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOCHEMISTRY; BLOOD ANALYSIS; BONE MARROW; BONE MASS; CELL CONTACT; CELL COUNT; CELL DAMAGE; CELL FUNCTION; CELL INTERACTION; CELL LINEAGE; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMUR; IN VITRO STUDY; IN VIVO STUDY; MEGAKARYOCYTE; MIXED CELL CULTURE; MORPHOMETRICS; MOUSE; MOUSE MUTANT; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PARAMETER; PHENOTYPE; PROTEIN DEFICIENCY; PROTEIN SECRETION; TRABECULAR BONE; URINALYSIS; WILD TYPE; ANIMAL; BIOSYNTHESIS; BONE DENSITY; BONE DEVELOPMENT; CELL COMMUNICATION; CELL CULTURE; CELL DIFFERENTIATION; CELL DIVISION; CYTOLOGY; GENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIOGRAPHY; TIBIA; ULTRASTRUCTURE;

ALKALINE PHOSPHATASE; ANIMALS; BONE DENSITY; BONE DEVELOPMENT; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL DIVISION; CELLS, CULTURED; DNA-BINDING PROTEINS; ERYTHROID-SPECIFIC DNA-BINDING FACTORS; FEMUR; GATA1 TRANSCRIPTION FACTOR; MEGAKARYOCYTES; MICE; MICE, KNOCKOUT; NF-E2 TRANSCRIPTION FACTOR; NF-E2 TRANSCRIPTION FACTOR, P45 SUBUNIT; OSTEOBLASTS; OSTEOCALCIN; OSTEOCLASTS; TIBIA; TRANSCRIPTION FACTORS;

EID: 3142669441     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.0301254     Document Type: Article

References (57)

1. Udagawa N, Takahashi N, Akatsu T, Sasaki T, Yamaguchi A, Kodama H, Martin TJ, Suda T 1989 The bone marrow-derived stromal cell line MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology 125:1805-1813.
2. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y-X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
3. Yasuda H 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
4. Kong Y-Y, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle W, Penninger JM 1999 Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309.
5. Kong Y-Y, Yoshida H, Sarosi I, Tan H-L, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323.
6. Thiede MA, Smock SL, Petersen DN, Grasser WA, Thompson DD, Nishimoto SK 1994 Presence of messenger ribonucleic acid encoding osteocalcin, a marker of bone turnover, in bone marrow megakaryocytes and peripheral blood platelets. Endocrinology 135:929-937.
7. Kelm RJ Jr, Hair GA, Mann KG, Grant BW 1992 Characterization of human osteoblast and megakaryocyte-derived osteonectin (SPARC). Blood 80:3112-3119.
8. Breton-Gorius J, Clezardin P, Guichard J, Debili N, Malaval L, Vainchenker W, Cramer EM, Delmas PD 1992 Localization of platelet osteonectin at the internal face of the α-granule membranes in platelets and megakaryocytes. Blood 79:936-941.
9. Chenu C, Delmas PD 1992 Platelets contribute to circulating levels of bone sialoprotein in humans. J Bone Miner Res 7:47-54.
10. FranK JD, Balena R, Masarachia P, Seedor JG, Cartwright ME 1993 The effects of three different demineralization agents on osteopontin localization in adult rat bone using immunohistochemistry. Histochemistry 99:295-301.
11. Orkin SH 1992 GATA-binding transcription factors in hematopoietic cells. Blood 80:575-581.
12. Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA 1999 Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood 93:2867-2875.
13. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, Jackson CW, Hunt P, Saris C, Orkin SH 1995 Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 81:695-704.
14. Vannucchi AM, Bianchi L, Cellai C, Paoletti F, Rana RA, Lorenzini R, Migliaccio G, Migliaccio AR 2002 Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood 100:1123-1132.
15. Yan X-Q, Lacey D, Fletcher F, Hartley C, McElroy P, Sun Y, Xia M, Mu S, Saris C, Hill D, Hawley RG, McNiece IK 1995 Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 86:4025-4033.
16. Yan X-Q, Lacey D, Hill D, Chen Y, Fletcher F, Hawley RG, McNiece IK 1996 A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): Reversal of disease by bone marrow transplantation. Blood 88:402-409.
17. Villeval J-L, Cohen-Solal K, Tulliez M, Giraudier S, Guichard J, Burstein SA, Cramer EM, Vainchenker W, Wendung F 1997 High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 90:4369-4383.
18. Shivdasani RA, Fielder P, Keller G-A, Orkin SH, de Sauvage FJ 1997 Regulation of the serum concentration of thrombopoietin in thrombocytopenic NF-E2 knockout mice. Blood 90:1821-1827.
19. Shivdasani RA, Mayer EL, Orkin SH 1995 Absence of blood formation in mice lacking the T-cell leukemia oncoprotein tal-1/SCL. Nature 373:432-434.
20. McDevitt MA, Shivdasani RA, Fujiwara Y, Yang H, Orkin SH 1997 A "knockdown" mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci USA 94:6781-6785.
21. Shivadasani RA, Fujiwara Y, McDevitt MA, Orkin SH 1997 A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J 16:3965-3973.
22. Ware CB, Horowitz MC, Renshaw BR, Hunt JS, Liggitt D, Koblar S, Gliniak BC, McKenna HJ, Peshon JJ, Stamatoyannopoulos G, Papayannopoulou T, Thoma B, Cheng L, Donavan PJ, Bartlett PF, Willis CR, Wright BD, Carpenter MK, Davison BL, Gearing DP 1995 Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene results in placental, skeletal and neural defects that result in perinatal death. Development 121:1283-1299.
23. Baron R, Ross R, Vignery A 1984 Evidence of sequential remodeling in rat trabecular bone morphology, dynamic histomorphometry, and changes during skeletal maturation. Anat Rec 208:137-145.
24. Sheehan DC, Hrapchak BB 1980 Connective tissue and muscle fiber stains. In: Theory and Practice of Histotechnology, 2nd ed. The C. V. Mosby Company, St. Louis, MO, USA, pp. 180-201.
25. Parfitt A, Drezner M, Glorieux F, Kanis J, Malluche H, Meunier P, Ott S, Recker R 1987 Bone histomorphometry: Standardization of nomenclature, symbols and units. J Bone Miner Res 2:595-609.
26. Ruegsegger P, Koller B, Muller R 1996 A microtomographic system for the nondestructive evaluation of bone architecture. Calcif Tissue Int 58:24-29.
27. Alexander JM, Bab I, Fish S, Muller R, Uchigama T, Gronowicz G, Nahounou M, Zhao Q, White DW, Chorev M, Gazit D, Rosenblatt M 2001 Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J Bone Miner Res 16:1665-1673.
28. Hildebrand T, Laib A, Muller R, Dequeker J, Ruegsegger P 1999 Direct three-dimensional morphometric analysis of human cancellous bone: Microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 14:1167-1174.
29. Horowitz MC, Fields A, DeMeo D, Qian H-Y, Bothwell A, Trepman E 1994 Expression and regulation of Ly-6 differentiation antigens by murine osteoblasts. Endocrinol 135:1032-1043.
30. Drachman JG, Sabath DF, Fox NE, Kaushansky K 1997 Thrombopoietin signal transduction in purified murine megakaryocytes. Blood 89:483-492.
31. Lecine P, Blank V, Snivdasani R 1998 Characterization of the hematopoietic transcription factor NF-E2 in primary murine megakaryocytes. J Biol Chem 273:572-7578.
32. Centrella M, McCarthy TL, Canalis E 1991 Glucocorticoide regulation of transforming growth factor β1 (TGF-β1) activity and binding in osteoblast-enriched cell cultures from fetal rat bone. Mol Cell Biol 11:4490-4496.
33. Gerstenfeld LC, Toma CD, Schaffer JL, Landis WJ 1998 Chondrogenic potential of skeletal cell populations: Selective growth of chondrocytes and their morphogenesis and development in vitro. Microsc Res Tech 43:156-173.
34. Gundberg CM, Clough ME, Carpenter TO 1992 Development and validation of a radioimmunoassay for mouse osteocalcin: Paradoxical response in the Hyp mouse. Endocrinology 130:1909-1915.
35. Yasuda H, Shima N, Nakagawa N, Mochizuki S-I, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 39:1329-1337.
36. Dempster DW, Murrills RJ, Horbert WR, Arnett TR 1987 Biological activity of chicken calcitonin: Effects on neonatal rat and embryonic chick osteoclasts. J Bone Miner Res 2:443-448.
37. Thomas PS 1980 Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci USA 77:5201-5205.
38. Sabatakos G, Sims NA, Chen J, Aoki K, Kelz MB, Amling M, Bouali Y, Mukhopadhyay K, Ford K, Nestler EJ, Baron R 2000 Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat Med 6:985-990.
39. Jochum W, David JP, Elliott C, Wutz A, Plenk H Jr, Matsuo K, Wagner EF 2000 Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med 6:980-984.
40. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, Karsenty G 1996 Increased bone formation in osteocalcin-deficient mice. Nature 382:448-452.
41. Mosekilde L, Danielsen CC, Sogaard CH, McOsker JE, Wronski TJ 1995 The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength-assessed in a sexually mature, ovariectomized rat model. Bone 16:223-230.
42. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G 2000 Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 100:197-207.
43. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Xintong H, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Eerdewegh PV, Recker RR, Johnson ML 2000 A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19.
44. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP 2002 High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521.
45. Metcalf D, Gearing DP 1989 A myelosclerotic syndrome in mice engrafted with cells producing high levels of leukemia inhibitory factor (LIF). Leukemia 3:847-852.
46. Malik N, Haugen HS, Modrell B, Shoyab M, Clegg CH 1995 Developmental abnormalities in mice transgenic for bovine oncostatin M. Mol Cell Biol 15:2349-2358.
47. Edwards MW, Bain SD, Bailey MC, Lantry MM, Howard GA 1992 17 beta estradiol stimulation of endosteal bone formation in the ovariectomized mouse: An animal model for the evaluation of bone-targeted estrogens. Bone 13:29-34.
48. Dunstan CR, Boyce R, Boyce BF, Garrett IR, Izbicka E, Burgess WH, Mundy GR 1999 Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats. J Bone Miner Res 14:953-959.
49. Mitlak BH, Finkelman RD, Hill EL, Li J, Martin B, Smith T, D'Andrea M, Antoniades HN, Lynch SE 1996 The effect of systemically administered PDGF-BB on the rodent skeleton. J Bone Miner Res 11:238-247.
50. Marcelli C, Mundy GR, Yates AJ 1990 In vivo effects of human recombinant transforming growth factor beta on bone turnover in normal mice. J Bone Miner Res 5:1087-1096.
51. Frey BM, Rafii S, Teterson M, Eaton D, Crystal RG, Moore MAS 1998 Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: Insights into the pathophysiology of osteomyelofibrosis. J Immunol 160:691-699.
52. Chagraoui H, Tulliez M, Smayra T, Komura E, Giraudier S, Yun T, Lassau N, Vainchenker W, Wendung F 2003 Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood 101:2983-2989.
53. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F 2002 Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 100:3495-3503.
54. Groopman JE 1980 The pathogenesis of myelofibrosis in myeloproliferative disorders. Ann Intern Med 92:857-858.
55. Gilbert HS 1984 Myelofibrosis revisited: Characterization and classification of myelofibrosis in the setting of myeloproliferative disease. In: Berk PD, Castro-Malaspina H, Wasserman LR (eds.) Myelofibrosis and the Biology of Connective Tissue. Liss, New York, NY, USA, pp. 3-17.
56. Terui T, Niitsu Y, Mahara K, Fujisaki Y, Urushizaki Y, Mogi Y, Kohgo Y, Watanabe N, Ogura M, Saito H 1990 The production of transforming growth factor-β in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood 75:1540-1548.
57. Martyre M 1995 TGF-β and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Leuk Lymphoma 20:39-44.